Nonalcoholic fatty liver disease and Type 2 diabetes mellitus
Open accessThe DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.
Abstract
Type 2 diabetes mellitus (T2DM) and nonalcoholic fatty liver disease (NAFLD) commonly exist together. It has been regarded as a manifestation of the metabolic syndrome. The presentations of NAFLD range from simple steatosis (NAFL), nonalcoholic steatohepatitis (NASH), and cirrhosis. NAFLD has a prevalence of 70% among T2DM patients. Overweight/obesity and insulin resistance (IR) have been strongly linked with NAFLD. Noninvasive assessment and staging of disease are based on clinical parameters such as age, sex, liver function test, platelet count, lipid profile, BMI, and imaging modalities such as USG, transient elastography (TE), and magnetic resonance imaging mass spectroscopy. Such clinical scoring systems and TE are useful in the early detection of NAFLD and predicting fibrosis. The principle behind the management of NAFLD with T2DM involves an indirect effect through improvement in IR and glycemia and thus is used for the treatment of T2DM as well.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chalasani, N., Younossi, Z., Lavine, J. E., Charlton, M., Cusi, K., Rinella, M., Harrison, S. A., Brunt, E. M., & Sanyal, A. J. (2018) · Hepatology · doi:10.1002/hep.29367 · Cited by 7,239
EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease
(2016) · Journal of Hepatology · doi:10.1016/j.jhep.2015.11.004 · Cited by 4,836
Chalasani, N., Younossi, Z., Lavine, J. E., Diehl, A. M., Brunt, E. M., Cusi, K., Charlton, M., & Sanyal, A. J. (2012) · Hepatology · doi:10.1002/hep.25762 · Cited by 3,803
Prevalence of Hepatic Steatosis in An Urban Population in the United States: Impact of Ethnicity
Browning, J. D., Szczepaniak, L. S., Dobbins, R., Nuremberg, P., Horton, J. D., Cohen, J. C., Grundy, S. M., & Hobbs, H. H. (2004) · Hepatology · doi:10.1002/hep.20466 · Cited by 3,664
Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
Sanyal, A. J., Chalasani, N., Kowdley, K. V., McCullough, A., Diehl, A. M., Bass, N. M., Neuschwander-Tetri, B. A., Lavine, J. E., Tonascia, J., Unalp, A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907929 · Cited by 3,327
Neuschwander-Tetri, B. A., Loomba, R., Sanyal, A. J., Lavine, J. E., Van Natta, M. L., Abdelmalek, M. F., Chalasani, N., Dasarathy, S., Diehl, A. M., Hameed, B., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61933-4 · Cited by 2,237
Singh, S., Allen, A. M., Wang, Z., Prokop, L. J., Murad, M. H., & Loomba, R. (2015) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2014.04.014 · Cited by 1,748
Ratziu, V., Harrison, S. A., Francque, S., Bedossa, P., Lehert, P., Serfaty, L., Romero-Gomez, M., Boursier, J., Abdelmalek, M., Caldwell, S., et al. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.01.038 · Cited by 1,035
Cusi, K., Orsak, B., Bril, F., Lomonaco, R., Hecht, J., Ortiz-Lopez, C., Tio, F., Hardies, J., Darland, C., Musi, N., et al. (2016) · Annals of Internal Medicine · doi:10.7326/m15-1774 · Cited by 1,024 · cited 13×
“[46] Improvement in fibrosis, insulin sensitivity in liver, skeletal muscle, and adipose tissue was also present;[46] the positive outcomes were maintained even after 36 months of treatment.[46] To sum up, it has a role in biopsy-proven NASH with T2DM.”
BackgroundInfluentialTargher, G., Bertolini, L., Rodella, S., Tessari, R., Zenari, L., Lippi, G., & Arcaro, G. (2007) · Diabetes Care · doi:10.2337/dc07-0349 · Cited by 579
Non-alcoholic fatty liver disease and diabetes
Hazlehurst, J. M., Woods, C., Marjot, T., Cobbold, J. F., & Tomlinson, J. W. (2016) · Metabolism · doi:10.1016/j.metabol.2016.01.001 · Cited by 527
Tiikkainen, M., Häkkinen, A.-M., Korsheninnikova, E., Nyman, T., Mäkimattila, S., & Yki-Järvinen, H. (2004) · Diabetes · doi:10.2337/diabetes.53.8.2169 · Cited by 524
Pais, R., Charlotte, F., Fedchuk, L., Bedossa, P., Lebray, P., Poynard, T., & Ratziu, V. (2013) · Journal of Hepatology · doi:10.1016/j.jhep.2013.04.027 · Cited by 522
Ryysy, L., Häkkinen, A. M., Goto, T., Vehkavaara, S., Westerbacka, J., Halavaara, J., & Yki-Järvinen, H. (2000) · Diabetes · doi:10.2337/diabetes.49.5.749 · Cited by 431 · cited 6×
“[25] DNL is further enhanced by IR.”
BackgroundInfluentialSvegliati‐Baroni, G., Saccomanno, S., Rychlicki, C., Agostinelli, L., De Minicis, S., Candelaresi, C., Faraci, G., Pacetti, D., Vivarelli, M., Nicolini, D., et al. (2011) · Liver International · doi:10.1111/j.1478-3231.2011.02462.x · Cited by 405 · cited 4×
“[48] DDP-IV inhibition resulted in an improved glycemic control with reduced AST and ALT in a small, nonrandomized study of individuals with ultrasonographic steatosis.[50] Treatment with DDP-IV inhibitors for 6 months resulted in reduced hepatic triglyceride as measured by MRS in a prospective blinded randomized cont…”
BackgroundMethodInfluentialNonalcoholic fatty liver disease and chronic vascular complications of diabetes mellitus
Targher, G., Lonardo, A., & Byrne, C. D. (2018) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2017.173 · Cited by 397
Pentoxifylline improves nonalcoholic steatohepatitis: A randomized placebo-controlled trial
Zein, C. O., Yerian, L. M., Gogate, P., Lopez, R., Kirwan, J. P., Feldstein, A. E., & McCullough, A. J. (2011) · Hepatology · doi:10.1002/hep.24544 · Cited by 356
Ix, J. H., & Sharma, K. (2010) · Journal of the American Society of Nephrology · doi:10.1681/asn.2009080820 · Cited by 348
Glucagon-like peptide-1 reduces hepatic lipogenesis via activation of AMP-activated protein kinase
Ben-Shlomo, S., Zvibel, I., Shnell, M., Shlomai, A., Chepurko, E., Halpern, Z., Barzilai, N., Oren, R., & Fishman, S. (2011) · Journal of Hepatology · doi:10.1016/j.jhep.2010.09.032 · Cited by 328
du Plessis, J., van Pelt, J., Korf, H., Mathieu, C., van der Schueren, B., Lannoo, M., Oyen, T., Topal, B., Fetter, G., Nayler, S., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.05.044 · Cited by 325
Singh, S., Singh, P. P., Singh, A. G., Murad, M. H., & Sanchez, W. (2013) · American Journal of Gastroenterology · doi:10.1038/ajg.2013.5 · Cited by 320
Targher, G., & Byrne, C. D. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-3093 · Cited by 297
Valenti, L., Fracanzani, A. L., Dongiovanni, P., Bugianesi, E., Marchesini, G., Manzini, P., Vanni, E., & Fargion, S. (2007) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2007.01192.x · Cited by 290
The role of adiponectin in the pathogenesis and treatment of non‐alcoholic fatty liver disease
Polyzos, S. A., Kountouras, J., Zavos, C., & Tsiaousi, E. (2010) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2009.01176.x · Cited by 277
Trevaskis, J. L., Griffin, P. S., Wittmer, C., Neuschwander-Tetri, B. A., Brunt, E. M., Dolman, C. S., Erickson, M. R., Napora, J., Parkes, D. G., & Roth, J. D. (2012) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00476.2011 · Cited by 277
Topping, D. L., & Mayes, P. A. (1972) · Biochemical Journal · doi:10.1042/bj1260295 · Cited by 275
An Assessment of Statin Safety by Hepatologists
Cohen, D. E., Anania, F. A., & Chalasani, N. (2006) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2005.12.014 · Cited by 269
Bower, G., Toma, T., Harling, L., Jiao, L. R., Efthimiou, E., Darzi, A., Athanasiou, T., & Ashrafian, H. (2015) · Obesity Surgery · doi:10.1007/s11695-015-1691-x · Cited by 256
Inflammatory and metabolic biomarkers and risk of liver and biliary tract cancer
Aleksandrova, K., Boeing, H., Nöthlings, U., Jenab, M., Fedirko, V., Kaaks, R., Lukanova, A., Trichopoulou, A., Trichopoulos, D., Boffetta, P., et al. (2014) · Hepatology · doi:10.1002/hep.27016 · Cited by 211
Relationship of sitting time and physical activity with non-alcoholic fatty liver disease
Ryu, S., Chang, Y., Jung, H.-S., Yun, K. E., Kwon, M.-J., Choi, Y., Kim, C.-W., Cho, J., Suh, B.-S., Cho, Y. K., et al. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.07.010 · Cited by 209
Bazick, J., Donithan, M., Neuschwander-Tetri, B. A., Kleiner, D., Brunt, E. M., Wilson, L., Doo, E., Lavine, J., Tonascia, J., & Loomba, R. (2015) · Diabetes Care · doi:10.2337/dc14-1239 · Cited by 206
How big a problem is non-alcoholic fatty liver disease?
Anstee, Q. M., McPherson, S., & Day, C. P. (2011) · BMJ · doi:10.1136/bmj.d3897 · Cited by 200
Kotronen, A., Juurinen, L., Hakkarainen, A., Westerbacka, J., Cornér, A., Bergholm, R., & Yki-Järvinen, H. (2008) · Diabetes Care · doi:10.2337/dc07-1463 · Cited by 196 · cited 1×
“asymptomatic T2DM patients with normal liver function tests (LFTs) is 20%.[7] This suggests that serum liver”
BackgroundRoux‐en‐Y Gastric Bypass Improves Liver Histology in Patients with Non‐Alcoholic Fatty Liver Disease
Clark, J. M., Alkhuraishi, A. R. A., Solga, S. F., Alli, P., Diehl, A. M., & Magnuson, T. H. (2005) · Obesity Research · doi:10.1038/oby.2005.140 · Cited by 184
Pentoxifylline for the treatment of non-alcoholic steatohepatitis: a randomized controlled trial
Van Wagner, L. B., Koppe, S. W. P., Brunt, E. M., Gottstein, J., Gardikiotes, K., Green, R. M., & Rinella, M. E. (2011) · Annals of Hepatology · doi:10.1016/s1665-2681(19)31539-x · Cited by 173
Yamazaki, H., Tsuboya, T., Tsuji, K., Dohke, M., & Maguchi, H. (2015) · Diabetes Care · doi:10.2337/dc15-0140 · Cited by 172
Dasarathy, S., Dasarathy, J., Khiyami, A., Yerian, L., Hawkins, C., Sargent, R., & McCullough, A. J. (2015) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0000000000000099 · Cited by 163
Nonalcoholic Fatty Liver Disease: Current Issues and Novel Treatment Approaches
Lomonaco, R., Sunny, N. E., Bril, F., & Cusi, K. (2013) · Drugs · doi:10.1007/s40265-012-0004-0 · Cited by 158
Ford, R. J., Fullerton, M. D., Pinkosky, S. L., Day, E. A., Scott, J. W., Oakhill, J. S., Bujak, A. L., Smith, B. K., Crane, J. D., Blümer, R. M., et al. (2015) · Biochemical Journal · doi:10.1042/bj20150125 · Cited by 157
Juurinen, L., Tiikkainen, M., Häkkinen, A.-M., Hakkarainen, A., & Yki-Järvinen, H. (2007) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00133.2006 · Cited by 141 · cited 2×
“[33] While insulin enhances lipogenesis with decrease in lipid oxidation in vitro,[35] human studies show paradoxical improvement in liver fat, which could be attributed to increased TAG secretion, improved hepatic insulin sensitivity, and reduced gluconeogenesis.[36,37] Thus, in T2DM and across all the stages of NAFL…”
BackgroundBae, J. C., Cho, Y. K., Lee, W., Seo, H. I., Rhee, E., Park, S. E., Park, C., Oh, K. W., Sung, K., & Kim, B. I. (2010) · The American Journal of Gastroenterology · doi:10.1038/ajg.2010.275 · Cited by 140
Tang, A., Rabasa-Lhoret, R., Castel, H., Wartelle-Bladou, C., Gilbert, G., Massicotte-Tisluck, K., Chartrand, G., Olivié, D., Julien, A.-S., de Guise, J., et al. (2015) · Diabetes Care · doi:10.2337/dc14-2548 · Cited by 133
Hayashizaki, Y., Kurosaki, E., Takasu, T., Mitori, H., Yamazaki, S., Koide, K., & Takakura, S. (2015) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2015.02.009 · Cited by 112
Chen, T., Lin, C., Huang, P., & Wen, C. (2011) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2011.06664.x · Cited by 107
Sphingolipids: agents provocateurs in the pathogenesis of insulin resistance
Lipina, C., & Hundal, H. S. (2011) · Diabetologia · doi:10.1007/s00125-011-2127-3 · Cited by 83 · cited 10×
“[25] DNL is further enhanced by IR.”
BackgroundInfluentialAssociation between the Fatty Liver Index and Risk of Type 2 Diabetes in the EPIC-Potsdam Study
Jäger, S., Jacobs, S., Kröger, J., Stefan, N., Fritsche, A., Weikert, C., Boeing, H., & Schulze, M. B. (2015) · PLoS ONE · doi:10.1371/journal.pone.0124749 · Cited by 70
Transient elastography in non-alcoholic fatty liver disease
Abenavoli, L., & Beaugrand, M. (2012) · Annals of Hepatology · doi:10.1016/s1665-2681(19)31021-x · Cited by 59
Thiazolidinediones and the liver in humans
Yki-Järvinen, H. (2009) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e3283321d37 · Cited by 59
Armstrong, M. J., Hazlehurst, J. M., Parker, R., Koushiappi, E., Mann, J., Khan, S., Philips, A., Chandler, L., Johnson, J., Round, M., et al. (2014) · QJM: An International Journal of Medicine · doi:10.1093/qjmed/hct198 · Cited by 53
Mills, E. P., Brown, K. P. D., Smith, J. D., Vang, P. W., & Trotta, K. (2017) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018817741852 · Cited by 41
Hillenbrand, A., Kiebler, B., Schwab, C., Scheja, L., Xu, P., Henne‐Bruns, D., Wolf, A. M., & Knippschild, U. (2015) · BMC Research Notes · doi:10.1186/s13104-015-1224-7 · Cited by 31
Bhatt, K., Pranav, V., Dipika, Y., Dharmesh, N., Nittala, R., & Arvind, S. (2017) · Journal of Mahatma Gandhi Institute of Medical Sciences · doi:10.4103/0971-9903.202001 · Cited by 16
Zammit, V. A. (2000) · Biochemical Society Transactions · doi:10.1042/bst0280103 · Cited by 13
Armstrong, M. J., Gaunt, P., Aithal, G. P., et al. (2015) · Journal of Hepatology · doi:10.1016/s0168-8278(15)30002-7 · Cited by 13
Diabetes Mellitus, Insulin, Sulfonylurea and Advanced Fibrosis in Non-Alcoholic Fatty Liver Disease
BoonBee, G. (2014) · Journal of Diabetes & Metabolism · doi:10.4172/2155-6156.1000410 · Cited by 11
Jun, D. W., Kim, H. J., Bae, J. H., & Lee, O. Y. (2011) · Hepatogastroenterology · doi:10.5754/hge10729 · Cited by 9
Matsumoto, N., Arase, Y., Kawamura, Y., Ohmoto-Sekine, M., Amakawa, K., Ogawa, K., Tsuji, H., Dong, H. S., Hara, S., Akuta, N., et al. (2015) · Internal Medicine · doi:10.2169/internalmedicine.54.3437 · Cited by 7
Cited by
Cai, H., Qin, Y.-L., Shi, Z.-Y., Chen, J.-H., Zeng, M.-J., Zhou, W., Chen, R.-Q., & Chen, Z.-Y. (2019) · BMC Gastroenterology · doi:10.1186/s12876-019-1132-8 · Cited by 205
Darakjian, L., Deodhar, M., Turgeon, J., & Michaud, V. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094967 · Cited by 53
“NAFLD increases the incidence of T2DM and expedites the progress of complications later in life [12,13].”
BackgroundBamgboye, A. O., Oni, I. O., & Collier, A. (2021) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-020-03051-3 · Cited by 48
A Model of Hepatic Steatosis with Declined Viability and Function in a Liver-Organ-on-a-Chip
Wiriyakulsit, N., Keawsomnuk, P., Thongin, S., Ketsawatsomkron, P., & Muta, K. (2023) · Scientific Reports · doi:10.1038/s41598-023-44198-0 · Cited by 29
Errafii, K., Khalifa, O., Al-Akl, N. S., & Arredouani, A. (2022) · Biomedicines · doi:10.3390/biomedicines10051020 · Cited by 17
Metadata
- Authors
- Dharmalingam, M., & Yamasandhi, P.
- Affiliations
- M.S. Ramaiah Medical College (IN)
- Corresponding author
- Dharmalingam, Mala
- ORCID
- Dharmalingam, Mala
- Venue
- Indian Journal of Endocrinology and Metabolism
- Published
- 2018
- Volume
- 22
- Issue
- 3
- Pages
- 421
- ISSN
- 2230-8210 (ISSN-L)
- PMC
- PMC6063173
- OpenAlex
- W2883254287
- Cited by
- 239
- References
- 57
- Citations by year
- 2026: 18 · 2025: 38 · 2024: 46 · 2023: 45 · 2022: 37 · 2021: 32 · 2020: 16 · 2019: 7
- FWCI
- 1.97
- Type
- journal article
- Language
- en
- Open access
- diamond
- doi.org
- Licence
- cc-by-nc-sa
- Locations
- Indian Journal of Endocrinology and Metabolism (publishedVersion, cc-by-nc-sa)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-sa)
- PubMed Central (publishedVersion, cc-by-nc-sa)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Keywords
- non-alcoholic fatty liver disease, type 2 diabetes, metabolic syndrome, nonalcoholic steatohepatitis, liver cirrhosis, insulin resistance, obesity, NAFLD staging, transient elastography, noninvasive fibrosis assessment, glycemic control, comorbidities
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.